- FDA authorizes StemCells to conduct trial of product candidate in patients with age-related macular degeneration
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA removes clinical hold on trial of Idenix's investigational HCV therapy
- Discovery Labs' aerosol drug delivery system approved
- Merck's Janumet XR approved for type 2 diabetes
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Cytokinetics' CK-2017357 granted orphan drug status for ALS
Wednesday, March 10 2010 | Comments
What's This?
The Food and Drug Administration designated Cytokinetics Inc.'s lead drug candidate, CK-2017357, an orphan drug for the treatment of amyotrophic lateral sclerosis.The company plans to initiate a Phase II study of the investigational agent in patients with this disease during the first half of this year.
CK-2017357 selectively activates the fast skeletal troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle force, Cytokinetics noted. The compound could have potential application for treating diseases associated with aging, muscle wasting and neuromuscular dysfunction, it added.
Cytokinetics previously indicated it is moving away from the oncology area to focus its internal research and development efforts on muscle function and related therapeutic applications.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- White blood cell count in presence of elevated ESR, CRP level predicts infection status in patients undergoing total hip arthroplasty, researchers report
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Symptoms of early, delayed puberty demand close clinical attention, in spite of shifting norms for pubertal onset
- Low-dose doxepin improves wake after sleep onset among individuals with primary insomnia, data indicate
- School-based nutrition, exercise intervention program may not maintain BMI decreases through 10 months in overweight students, data indicate
- Careful discharge planning, follow-up vital for high-risk neonates facing hospital discharge, updated AAP guidelines state
- Nissen fundoplication in children with GERD reduces need for antireflux medication, researchers find
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
